PMID- 12678540
OWN - NLM
STAT- MEDLINE
DCOM- 20030515
LR  - 20131121
IS  - 1028-5229 (Print)
IS  - 1028-5229 (Linking)
VI  - 2
IP  - 5
DP  - 2001
TI  - Enoximone maintains intestinal villus blood flow during endotoxemia.
PG  - 359-67
AB  - BACKGROUND: The objective of this study was to determine the effects of a 
      continuous infusion of the phosphodiesterase inhibitor enoximone on mucosal 
      villus blood flow in a normotensive model of endotoxemia. METHODS: Twenty-four 
      anesthetized and ventilated rats underwent laparotomy and a ileal portion was 
      exteriorized and opened by an antimesenteric incision. The ileal segment was 
      fixed on a plexiglass stage with the mucosal surface upward. Microcirculatory 
      parameters were assessed by intravital videomicroscopy. The animals were randomly 
      assigned to receive one of three treatments: infusion of Escherichia coli 
      lipopolysaccharides (LPS, 2 mg/kg/h) without phosphodiesterase inhibitor 
      pretreatment (LPS group); or infusion of LPS with enoximone pretreatment (10 
      microg x kg(-1) x min(-1), start 30 min before LPS infusion, enoximone group), or 
      infusion of an eqivalent volume of NaCl 0.9% (control group). Macrohemodynamic 
      parameters (MAP, HR) and microhemodynamic parameters of ileal mucosa (mean 
      diameter of central arterioles = DA, and mean erythrocyte velocity within the 
      arterioles = VE) were measured 30 min before and at 0, 60, and 120 min after 
      induction of endotoxemia. Mucosal villus blood flow was calculated from DA and 
      VE. RESULTS: In this normotensive endotoxemia model MAP remained stable in the 
      control and the LPS group but significantly decreased in the enoximone group. The 
      endotoxin-induced decrease of VE and DE of central arterioles of mucosal villi 
      could be prevented. Thus, mucosal villus blood flow did not decrease compared to 
      the LPS group. CONCLUSIONS: Our results indicate that enoximone during an early 
      stage of sepsis contributes to systemic hypotension but prevents mucosal 
      hypoperfusion.
FAU - Schmidt, W
AU  - Schmidt W
AD  - Department of Anesthesiology, University of Heidelberg, Im Neuenheimer Feld 110, 
      D-69120 Heidelberg, Germany. werner.schmidt@urz.uni-heidelberg.de
FAU - Tinelli, M
AU  - Tinelli M
FAU - Secchi, A
AU  - Secchi A
FAU - Gebhard, M
AU  - Gebhard M
FAU - Martin, E
AU  - Martin E
FAU - Schmidt, H
AU  - Schmidt H
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Switzerland
TA  - Int J Surg Investig
JT  - International journal of surgical investigation
JID - 100965774
RN  - 0 (Phosphodiesterase Inhibitors)
RN  - C7Z4ITI7L7 (Enoximone)
SB  - IM
MH  - Analysis of Variance
MH  - Animals
MH  - Disease Models, Animal
MH  - Endotoxemia/*drug therapy
MH  - Enoximone/*pharmacology
MH  - Escherichia coli
MH  - Hemodynamics/drug effects
MH  - Infusions, Intravenous
MH  - Intestinal Mucosa/*blood supply/*drug effects
MH  - Laparotomy
MH  - Male
MH  - Microcirculation/drug effects
MH  - Phosphodiesterase Inhibitors/*pharmacology
MH  - Probability
MH  - Random Allocation
MH  - Rats
MH  - Rats, Wistar
MH  - Reference Values
MH  - Sensitivity and Specificity
EDAT- 2003/04/08 05:00
MHDA- 2003/05/16 05:00
CRDT- 2003/04/08 05:00
PHST- 2003/04/08 05:00 [pubmed]
PHST- 2003/05/16 05:00 [medline]
PHST- 2003/04/08 05:00 [entrez]
PST - ppublish
SO  - Int J Surg Investig. 2001;2(5):359-67.